Cabergoline 0.25 mg Tab
| Product Overview | |
| Generic Name | Cabergoline 0.25 mg Tab |
| Brand Name(s) | Dostinex, Cabgolin |
| Form | Oral tablets |
| Strength | 0.25 mg |
| Therapeutic Class | Treatment of hyperprolactinemia; also uses in Parkinson’s disease and lactation suppression |
| ATC Code | G02CB03 |
| Manufacturing & Regulatory | |
| Manufacturer | Pfizer, Sun Pharmaceutical Ltd |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Full CTD dossier proprietary; available under commercial agreement/license |
Description
Indications & Usage: Cabergoline is indicated for treatment of hyperprolactinemia (e.g. prolactinomas, amenorrhea, infertility, galactorrhea) at initial adult dose of 0.25 mg twice weekly with titration up to 1 mg twice weekly as needed. Mechanism: long‑acting dopamine D₂ agonist inhibiting prolactin secretion.
